Get the Stockscreener App
2.875
13.40%
-0.445
After Hours:
2.33
-0.545
-18.96%
Humacyte Inc stock is traded at $2.875, with a volume of 4.50M.
It is down -13.40% in the last 24 hours and down -5.43% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$3.32
Open:
$3.01
24h Volume:
4.50M
Relative Volume:
1.16
Market Cap:
$427.18M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.6869
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-8.15%
1M Performance:
-5.43%
6M Performance:
-47.30%
1Y Performance:
-8.44%
1-Day Range:
$2.8601
$3.10
1-Week Range:
$2.8601
$3.36
52-Week Range:
$2.75
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.875 | 427.18M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte sets $2 stock offering, aims for $50 million - Investing.com
Humacyte Prices Public Offering Of 25 Million Shares At $2.00 Per Share - Marketscreener.com
Humacyte Secures $50M Funding: Major Push for SYMVESS Commercialization - StockTitan
Humacyte Shares Plunge After Hours: Here's Why - Benzinga
Humacyte announces public stock offering for expansion - Investing.com India
Humacyte down 13% amid reports that FDA approved device despite warnings - Seeking Alpha
Humacyte Announces Proposed Public Offering Of Common Stock - Marketscreener.com
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know - MSN
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) - Seeking Alpha
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - ACCESS Newswire
Individual investors who hold 41% of Humacyte, Inc. (NASDAQ:HUMA) gained 11%, institutions profited as well - Simply Wall St
HUMACYTE Earnings Preview: Recent $HUMA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Why Humacyte Stock Is Trading 15% Higher Monday - MSN
HC Wainwright Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - Defense World
HUMA stock touches 52-week low at $2.81 amid market shifts - Investing.com Australia
HUMA stock touches 52-week low at $2.81 amid market shifts By Investing.com - Investing.com South Africa
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential - TipRanks
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - The Manila Times
Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication - Nasdaq
New Study: Humacyte's Symvess Cuts Trauma Center Costs by $33,000 Per Patient - StockTitan
Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating - TipRanks
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital - Defense World
Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Benchmark maintains Humacyte stock Buy rating, $17 target - Investing.com India
Benchmark maintains Humacyte stock Buy rating, $17 target By Investing.com - Investing.com South Africa
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts - Defense World
Trestle Bio Announces Research Collaboration with Humacyte - BioSpace
Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research -March 06, 2025 at 09:16 am EST - Marketscreener.com
Humacyte, Trestle Biotherapeutics announce research collaboration - TipRanks
Can This Groundbreaking Biotech Partnership Solve the Kidney Transplant Crisis? - StockTitan
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - The Manila Times
Will Humacyte's First-in-Class Bioengineered Vessel Transform Trauma Care? Investors to Get Answers - StockTitan
Atria Wealth Solutions Inc. Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages - TipRanks
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Shareholder Rights Advocates at Levi & Korsinsky Investigate Humacyte, Inc. (HUMA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - MSN
Can Humacyte's Presentation at TD Cowen Conference Reveal New Bioengineered Tissue Breakthroughs? - StockTitan
Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System - Marketscreener.com
Humacyte secures patent for bioreactor system until 2040 By Investing.com - Investing.com South Africa
Humacyte secures patent for bioreactor system until 2040 - Investing.com India
Humacyte announces issuance of U.S. patent covering Symvess manufacturing - TipRanks
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):